Small-cell lung cancer with superior vena cava syndrome: facial/upper-extremity edema, di...

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`RF-SCLC-SVC-SYNDROME`
Type	Red flag
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-SCLC`
Sources	`SRC-ESMO-SCLC-2021` `SRC-NCCN-SCLC-2025`

Red Flag Origin

Definition	Small-cell lung cancer with superior vena cava syndrome: facial/upper-extremity edema, distended neck veins, dyspnea, plethora — SCLC is a top oncologic cause of SVC syndrome (alongside NSCLC and lymphoma)
Clinical direction	hold
Category	organ-dysfunction
Shifts algorithm	ALGO-SCLC-1L

Trigger Logic

{
  "any_of": [
    {
      "finding": "svc_syndrome_present",
      "value": true
    },
    {
      "finding": "facial_upper_extremity_edema",
      "value": true
    },
    {
      "finding": "distended_neck_veins",
      "value": true
    }
  ],
  "type": "composite"
}

Notes

SVC syndrome occurs in ~10% of SCLC at presentation. Per NCCN-SCLC + ESMO-SCLC 2021: SCLC is highly chemosensitive; cisplatin/carboplatin + etoposide first-line is preferred (not RT) when SVC is uncomplicated; endovascular SVC stenting ± urgent palliative RT (30 Gy/10 fx) for rapid relief if neurologic compromise. Direction HOLD on definitive systemic start until vascular access ensured + airway secured; priority 12. STUB — requires clinical co-lead signoff.

Used By

No reverse references found in the YAML corpus.